… Between February 1985 and August 1992, 121 adults in second or subsequent, complete
or partial remission of follicular lymphoma (Table 1) were treated with CY+TBI supported by …

… -ibritumomab tiuxetan to achieve durable remissions with observed median … durability of
response is unlikely to be accounted for by patient selection as most of these durable remissions …

… -dose ablative therapy in follicular lymphoma is based on the … /refractory NHLs, resistant
disease could be overcome with … alive and in remission from both follicular lymphoma and the …

… A number of phase 2 trials in previously untreated patients have demonstrated high
response rates with durable remissions in patients receiving first-line RIT as a single agent or …

… Bispecific antibodies provide an off-the-shelf form of T-cell mediated therapy, with the goal
of achieving the durable remissions seen with CAR T-cell therapy. Unlike CAR T-cell therapy, …

… -cell non-Hodgkin lymphoma (B-NHL) and B-cell acute lymphoblastic leukemia, a subset of
patients with disease refractory to available therapies will achieve durable remissions after a …

… the role of rituximab maintenance in elderly follicular lymphoma (FL) patients after a brief
first-… (A) PFS based on N-PCR and clinical remission at M8. (B) PFS based on N-PCR at M8 in …

… A substantial proportion of patients with FL achieve long-lasting remissions with rituximab …
at all before 90 YIT RIT in order to achieve long-lasting remission rates: here, we report on the …

Purpose This study is an integrated efficacy analysis of the five clinical trials of tositumomab
and iodine-131 tositumomab in patients with relapsed or refractory low-grade, follicular, or …

… first remission may permit successful treatment for patients before the development of resistant
… bcl-21 IgH rearrangement are in molecular remission at their last follow-up. Although still …